Table 2. Study outcomes.
| Reference | Comparison | Survival benefit | |||||
|---|---|---|---|---|---|---|---|
| Entire cohort | Node-positive disease | Stage | Positive resection margins | Grade | Histological subtype | ||
| Marchegiani, 2019 (15) | AT vs. surgery alone | No | Yes | NA | NA | NA | Tubular carcinoma |
| Duconseil, 2017 (16) | ACT vs. surgery alone | Yes | Yes | NA | NA | NA | NA |
| McMillan, 2016 (17) | AT vs. surgery alone | Yes | Yes | Stage II–IV | Yes | Poor differentiation | NA |
| Caponi, 2013 (18) | AT vs. surgery alone | Yes | Yes | NA | NA | NA | NA |
| Worni, 2012 (19) | AR vs. surgery alone | Yes | Yes | T3/T4 | NA | No | NA |
| Alexander, 2011 (20) | AT vs. surgery alone | No | Yes | NA | NA | NA | NA |
| Turrini, 2010 (21) | AT vs. surgery alone | No | No | No | No | NA | NA |
| Swartz, 2010 (22) | AT vs. surgery alone | Yes | Yes | NA | Yes | NA | NA |
ACT, adjuvant chemotherapy; AR, adjuvant radiotherapy; AT, adjuvant therapy; NA, not available.